An exceptionally high-quality franchise with a wide economic moat, elite-tier efficiency metrics, and strong upward price momentum now trades above its near-term take-profit target, leaving the risk/reward geometry unfavorable; the quality profile and rising analyst estimates are constructive over a longer horizon, but single-product concentration risk and high short interest make the current price unattractive for new entry.
Thesis pillars
- Exceptional Franchise Quality→Stable
- Price Above Take Profit Level↓Deteriorating
- Single Product Supplier Concentration↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 5, 2026
Liquidia Corporation (LQDA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $45.72, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Supplier: single suppliers for YUTREPIA.
Liquidia Corporation commercializes YUTREPIA (treprostinil inhalation powder), FDA-approved in May 2025 for pulmonary arterial hypertension and pulmonary hypertension-ILD, and shares profits from Sandoz's generic Treprostinil Injection under a 2018 promotion agreement. The... Read more
Sell if holding. At $45.72, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Supplier: single suppliers for YUTREPIA. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.6/10, high confidence.
Passes 5/9 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 4d<=7d. Suitability: speculative.
About Liquidia Corporation
About Liquidia Corporation
Liquidia Corporation launched YUTREPIA (treprostinil inhalation powder) in June 2025 following FDA approval in May 2025 for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also earns a profit share from Sandoz's generic Treprostinil Injection under a 2018 promotion agreement. Liquidia reported net losses of $68.9 million for the year ended December 31, 2025, and carried an accumulated deficit of $626.3 million despite achieving quarterly profitability in the third and fourth quarters of 2025.
Liquidia sells YUTREPIA through a targeted U.S. commercial field force and specialty pharmacies, distributing to healthcare providers who treat an estimated 45,000 PAH patients and approximately 60,000 PH-ILD patients in the United States. The company relies on single-source suppliers for the active pharmaceutical ingredient, the RS00 Model dry-powder inhaler, and encapsulation and packaging for YUTREPIA. Treprostinil Injection is manufactured and supplied entirely by Sandoz under Sandoz's ANDA; Liquidia PAH earns a profit share but holds no regulatory approval for that product. United Therapeutics has filed multiple patent and trade-secret lawsuits seeking injunctive relief that could remove YUTREPIA from the market. The pipeline's next major asset is L606, a liposomal treprostinil formulation licensed from Pharmosa Biopharm, currently in a global Phase 3 placebo-controlled efficacy study targeting 340 patients across more than 100 sites in at least 20 countries.
Show full overview
The L606 pivotal trial in PH-ILD represents Liquidia's primary source of future revenue diversification, and the 10-K warns that the trial may not succeed and that delays could increase costs and impair commercialization timelines. Simultaneously, the existing revenue base could be severely curtailed if United Therapeutics obtains the injunctive relief it seeks, which could remove YUTREPIA from the PAH and/or PH-ILD market before L606 is available as a substitute. These two binary risks — litigation outcome and trial readout — converge on the same narrow commercialization window.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Liquidia Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Liquidia Corporation
Latest news
- NEWS LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? - Zacks Investment Research — Zacks Investment Research neutral
- NEWS Liquidia Corp (LQDA) Shares Plunge 25% After Patent Dispute Cour - GuruFocus — GuruFocus negative
- NEWS Liquidia plunges amid court ruling in United Therapeutics patent fight - Seeking Alpha — Seeking Alpha negative
- NEWS LQDA260925P00049000 Interactive Stock Chart | LQDA Sep 2026 49.000 put Stock - Yahoo Finance — Yahoo Finance neutral
- NEWS Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock - MarketBeat — MarketBeat negative
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductYUTREPIA10-K Item 1A: 'We are primarily dependent on the success of YUTREPIA, for which we recently received FDA approval for the treatment of PAH and PH-ILD'
- HIGHSuppliersingle suppliers for YUTREPIA10-K Item 1A: 'We depend on third parties for clinical and commercial supplies, including single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA'
- MEDIUMcounterpartySandoz10-K Item 1A: 'Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection and is dependent on Sandoz to manufacture and supply Treprostinil Injection'
- MEDIUMpipelineL606 pivotal trial10-K Item 1A: 'our planned pivotal clinical trial of L606, may not be successful and delays in such preclinical studies or clinical trials may cause our costs to increase'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $45.72, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: YUTREPIA; Concentration risk — Supplier: single suppliers for YUTREPIA. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $42.52. Score 6.6/10, high confidence.
Analyst target: $47.31 (+3.5% upside). Prior stop was $42.52. Stop-loss: $42.52.
Concentration risk — Product: YUTREPIA; Concentration risk — Supplier: single suppliers for YUTREPIA; Thin upside margin: 3.5%.
Liquidia Corporation trades at a P/E of 32.9 (forward 20.9). TrendMatrix value score: 5.3/10. Verdict: Sell.
15 analysts cover LQDA with a consensus score of 4.1/5. Average price target: $54.
What does Liquidia Corporation do?Liquidia Corporation commercializes YUTREPIA (treprostinil inhalation powder), FDA-approved in May 2025 for pulmonary...
Liquidia Corporation commercializes YUTREPIA (treprostinil inhalation powder), FDA-approved in May 2025 for pulmonary arterial hypertension and pulmonary hypertension-ILD, and shares profits from Sandoz's generic Treprostinil Injection under a 2018 promotion agreement. The company reported net losses of $68.9 million in 2025 and carried an accumulated deficit of $626.3 million at year-end.